Iambic Therapeutics files for Nasdaq IPO to fund cancer drug programs

Iambic Therapeutics Inc. submitted a filing on Monday for an initial public offering on the Nasdaq Global Select Market, planning to list under the ticker IAM. The San Diego company applies artificial intelligence to create new therapies, and Nvidia Corp. (NASDAQ:NVDA) is among its shareholders.

The clinical-stage life sciences and technology company intends to direct IPO proceeds toward advancing three early-stage cancer treatments. Its lead candidate, IAM1363, is an oral small molecule inhibitor targeting human epidermal growth factor receptor 2 (HER2); as of September 2026, it is being evaluated in an ongoing Phase 1/1b basket trial involving patients with advanced HER2-altered solid tumors.

Iambic anticipates submitting Investigational New Drug applications for two other programs, IAM217 and IAM-C1, during the fourth quarter of 2026. IAM217 is a brain-penetrant allosteric inhibitor of KIF18A, a mitotic kinesin that may have therapeutic relevance in ovarian cancer and triple-negative breast cancer. IAM-C1 acts as a selective dual inhibitor of cyclin-dependent kinases 2 and 4.

As of September 18, 2026, the company had raised about $461.8 million from backers such as Catalio, Nexus Ventures, Q Healthcare Holding, Nvidia and Coatue Ventures. Its filing with the U.S. Securities and Exchange Commission did not reveal the number of shares to be offered or an expected price range.

J.P. Morgan, Jefferies, BofA Securities and Citigroup are acting as underwriters for the offering. The company has given the underwriters a 30-day option to buy additional shares.

This article was produced with assistance from AI and reviewed by an editor. See our terms and conditions for further details.